Antiepileptic drugs (AEDs) are commonly termed as anticonvulsants or antiseizure drugs, which are used in symptomatic treatment of epileptic seizures. The epileptic seizures show recurring episodes and occur due to wrong signal sent by nerve cells to the brain. Antiepileptic drugs also act as mood stabilizers and also used in the treatment of bipolar disorders or neuropathic pain.

The global Anti Epilepsy Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Anti Epilepsy Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anti Epilepsy Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Anti Epilepsy Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Anti Epilepsy Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Abbott Laboratories
Cephalon
Sunovion Pharmaceuticals
Valeant Pharmaceuticals
Sanofi
UCB Pharma
GlaxoSmithKline
Johnson & Johnson
Novartis
Pfizer

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
First Generation AEDs
Second Generation AEDs

Segment by Application
Partial
Generalized